Kirschfink M, Haferkamp A, Pomer S, Chrupcala M, Wosnik A, Heckl-Ostreicher B
Institut für Immunologie, Universität Heidelberg.
Zentralbl Chir. 1998;123(7):793-7.
Hyperacute graft rejection triggered by the activation of the recipient's complement system represents the major obstacle to successful xenotransplantation. After the binding of preformed antibodies to vascular glycoproteins complement-induced activation and injury of endothelial cells with subsequent thrombosis leads to rapid destruction of foreign tissues. Inhibition of complement activation is therefore considered as a prerequisite for xenograft survival. Recent animal and cell culture experiments suggest that support of the physiological regulation of the complement system appears to be most promising. Besides the application of soluble complement inhibitors (e.g. soluble complement receptor 1, sCR1; C1 inhibitor) the genetic transfer of human membrane-bound complement regulatory proteins (e.g. DAF, CD59) offers new chances to protect the xenograft against the cytolytic complement attack. Results from the authors' experiments shall be included in a short overview to the issue.
由受体补体系统激活引发的超急性移植排斥反应是成功进行异种移植的主要障碍。预先形成的抗体与血管糖蛋白结合后,补体诱导的内皮细胞激活和损伤以及随后的血栓形成会导致外来组织迅速破坏。因此,抑制补体激活被认为是异种移植物存活的先决条件。最近的动物和细胞培养实验表明,支持补体系统的生理调节似乎最有前景。除了应用可溶性补体抑制剂(如可溶性补体受体1,sCR1;C1抑制剂)外,人类膜结合补体调节蛋白(如衰变加速因子,DAF;CD59)的基因转移为保护异种移植物免受溶细胞性补体攻击提供了新的机会。作者的实验结果将纳入对该问题的简短概述中。